Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma

doi:10.4240/wjgs.v18.i5.116672

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(2)

(0)

(29)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. May 27, 2026; 18(5): 116672
Published online May 27, 2026. doi: 10.4240/wjgs.v18.i5.116672

Table 1 The relationship between serum aldo-keto reductase family 1 member B10 levels and clinical pathological characteristics of hepatocellular carcinoma patients, n (%)

Item	AKR1B10 (pg/mL)		χ²	P value
Item	< 1584.97 (n = 27)	≥ 1584.97 (n = 75)	χ²	P value
Gender			2.34	0.126
Male	19 (70.4)	63 (84.0)
Female	8 (29.6)	12 (16.0)
Age			0.026	0.872
< 65 years old	19 (70.4)	54 (72.0)
≥ 65 years old	8 (29.6)	21 (28.0)
Smoking history			1.137	0.286
Absent	14 (51.9)	30 (40.0)
Present	13 (48.1)	45 (60.0)
History of alcohol consumption			2.974	0.085
Absent	16 (59.3)	30 (40.0)
Present	11 (40.7)	45 (60.0)
Viral hepatitis				0.170¹
Absent	2 (7.4)	1 (1.3)
Present	25 (92.60)	74 (98.7)
Hepatic cirrhosis			0.027	0.87
Absent	5 (18.5)	11 (14.70)
Present	22 (81.5)	64 (85.3)
Antiviral therapy			0.276	0.6
Absent	15 (55.6)	46 (61.3)
Present	12 (44.4)	29 (38.7)
Number of tumors			1.541	0.215
1	16 (59.3)	34 (45.3)
≥ 1	11 (40.7)	41 (54.7)
Tumor size (cm)			3.999	0.046
< 5	19 (70.4)	36 (48.0)
≥ 5	8 (29.6)	39 (52.0)
Portal vein tumor thrombus			2.447	0.118
Absent	22 (81.5)	49 (65.3)
Present	5 (18.5)	26 (34.7)
Vascular tumor thrombus			0.417	0.518
Absent	27 (100)	71 (94.7)
Present	0 (0)	4 (5.3)
Metastasis to lymph nodes or distant metastasis			0.018	0.893
Absent	24 (88.9)	64 (85.3)
Present	3 (11.1)	11 (14.7)
Ascites			3.902	0.048
Absent	25 (92.6)	56 (74.7)
Present	2 (7.4)	19 (25.3)
Combined type 2 diabetes mellitus			1.043	0.167
Absent	26 (96.3)	65 (86.7)
Present	1 (3.7)	10 (13.3)
Microvascular invasion			0.33	0.566
Absent	24 (88.9)	71 (94.7)
Present	3 (11.1)	4 (5.3)
Satellite lesions				0.461¹
Absent	26 (96.3)	74 (98.7)
Present	1 (3.7)	1 (1.3)
BCLC staging			3.987	0.046
A + B	21 (77.8)	42 (56.0)
C + D	6 (22.2)	33 (44.0)
BMI index			1.159	0.282
< 25	21 (77.8)	50 (66.7)
≥ 25	6 (22.2)	25 (33.3)
AFP (ng/mL)			1.346	0.246
< 5.89	12 (44.4)	24 (32.0)
≥ 5.89	15 (55.6)	51 (68.0)
AFP (ng/mL)			1.852	0.174
< 20	16 (59.3)	33 (44.0)
≥ 20	11 (40.7)	42 (56.0)
AFP (ng/mL)			0.006	0.94
< 400	20 (74.1)	55 (73.3)
≥ 400	7 (25.9)	20 (26.7)
GLU (mmol/L)			0.512	0.474
3.9-6.1	22 (81.5)	56 (74.7)
≥ 6.1	5 (18.5)	19 (25.3)
PT (seconds)			1.773	0.183
9-13	22 (81.5)	51 (68.0)
≥ 13	5 (18.5)	24 (32.0)
ALT (U/L)			0.914	0.339
7-40	21 (77.8)	51 (68.0)
≥ 40	6 (22.2)	24 (32.0)
AST (U/L)			0.891	0.345
13-35	14 (51.9)	31 (41.3)
≥ 35	13 (48.1)	44 (58.7)
TBIL (umol/L)			1.701	0.192
≤ 21	20 (74.1)	45 (60.00)
≥ 21	7 (25.9)	30 (40.0)
ALB (g/L)			1.152	0.283
40-55	19 (70.4)	44 (58.7)
< 40	8 (29.6)	31 (41.3)

¹Indicates that the P-value was calculated by Fisher’s exact test.

BCLC: Barcelona Clinic Liver Cancer; BMI: Body mass index; AFP: Alpha-fetoprotein; GLU: Glucose; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; ALB: Albumin; AKR1B10: Aldo-keto reductase family 1 member B10.

Full Size Table

Table 2 Cox regression analysis of the influencing factors on the survival time of hepatocellular carcinoma patients

Factors	Univariate analysis		Multivariate analysis
Factors	HR (95%CI)	P value	HR (95%CI)	P value
Gender	1.103 (0.623-1.954)	0.736
Age	0.927 (0.577-1.489)	0.754
Smoking	1.349 (0.832-2.185)	0.224
Alcohol consumption	1.298 (0.807-2.087)	0.283
Viral hepatitis	1.203 (0.293-4.940)	0.797
Hepatic cirrhosis	0.793 (0.423-1.484)	0.468
Antiviral therapy	0.958 (0.612-1.586)	0.951
Number of tumors	1.261 (0.787-2.019)	0.336
Tumor size	1.617 (1.009-2.590)	0.046	1.346 (0.826-2.192)	0.233
Portal vein tumor thrombus	1.261 (0.761-2.091)	0.368
Vascular tumor thrombus	2.120 (0.767-5.856)	0.147
Metastasis to lymph nodes or distant metastasis	1.439 (0.755-2.743)	0.269
Ascites	2.249 (1.269-3.985)	0.006	1.810 (1.017-3.223)	0.044
Combined type 2 diabetes mellitus	1.139 (0.521-2.490)	0.744
Microvascular invasion	2.545 (1.076-6.024)	0.034	2.291 (0.963-5.452)	0.061
Satellite lesions	2.270 (0.547-9.429)	0.259
BCLC staging (AB/CD)	1.414 (0.879-2.273)	0.153
BMI index (≥ 25)	0.835 (0.492-1.415)	0.502
AFP (≥ 5.89 ng/mL)	1.518 (0.920-2.504)	0.102
AFP (≥ 20 ng/mL)	1.354 (0.845-2.170)	0.208
AFP (≥ 400 ng/mL)	1.728 (1.402-2.867)	0.034	1.469 (0.873-2.473)	0.148
GLU (≥ 6.1 mmol/L)	0.961 (0.549-1.683)	0.89
PT (≥ 13 seconds)	1.069 (0.654-1.747)	0.791
ALT (≥ 40 U/L)	1.343 (0.809-2.227)	0.254
AST (≥ 35 U/L)	1.335 (0.830-2.146)	0.234
TBIL (≥ 21 μmol/L)	1.182 (0.727-1.921)	0.5
ALB (≥ 55 g/L)	1.481 (0.919-2.388)	0.107
AKR1B10 (1584.97 pg/mL)	2.021 (1.137-3.593)	0.017	1.819 (1.009-3.280)	0.047

Full Size Table

Citation: Du YL, Shi CJ, Gao FY, Xie SJ, Zhang MN, Zhang ZQ, Qiu W, Ming Y. Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma. World J Gastrointest Surg 2026; 18(5): 116672
URL: https://www.wjgnet.com/1948-9366/full/v18/i5/116672.htm
DOI: https://dx.doi.org/10.4240/wjgs.v18.i5.116672

Du YL, Shi CJ, Gao FY, Xie SJ, Zhang MN, Zhang ZQ, Qiu W, Ming Y. Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma. World J Gastrointest Surg 2026; 18(5): 116672 [DOI: 10.4240/wjgs.v18.i5.116672]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.